13F Report Date vs Filing Date: How to Avoid 45-Day Timing Mistakes
Many investors misread 13F timing. Learn the difference between report date and filing date so you stop reacting to positions that were set weeks earlier.
Introduction
If you are new to 13F data, one timing detail causes most beginner mistakes: a filing can be published weeks after the positions were reported. In plain language, a 13F tells you what a manager held on the report date, but you often read it on the later filing date.
On 13F Insight, this matters because you might compare today’s market move to a portfolio snapshot from last quarter. If you do not account for the lag, you can mistake old positioning for a new trade.
Core Explanation: Report Date vs Filing Date
Report date is the portfolio snapshot date (quarter end, like 2025-12-31). Filing date is when the manager submits the 13F to the SEC, usually up to 45 days later.
- Report date answers: “What did they hold at quarter end?”
- Filing date answers: “When did the public learn about it?”
If a stock rallied sharply after quarter end, a big position in the filing does not automatically mean the fund bought into that rally. It may have held the position before the move.
Real Example From the Platform
As of the latest available quarter snapshot, several top managers show very large NVIDIA holdings on 13F Insight:
- Vanguard Group: 2,266,683,275 shares (reported value about $422.7B)
- BlackRock: 1,945,288,884 shares (reported value about $362.8B)
- State Street: 991,480,489 shares (reported value about $184.9B)
These numbers are valuable, but they are quarter-end snapshots. Use them as evidence of structural exposure, not proof of what was bought yesterday. You can inspect this directly on NVIDIA’s stock page and cross-check each manager profile such as Vanguard.
Step-by-Step: A Safer Reading Workflow
- Start with the quarter label (for example, 2025Q4) and identify the report date behind that quarter.
- Check position context on the stock page: is the holder list broad and persistent, or concentrated in a few managers?
- Compare sequential quarters before drawing conclusions about “new” buying. A stable large position is different from a sharp increase.
- Use filing-season awareness so you know when most updates arrive. The platform’s filing-season guide helps set expectations: 13F Filing Deadlines.
- Only then add a narrative such as conviction, rebalancing, or risk reduction.
Common Misconceptions
Misconception 1: “It was filed today, so it was bought today.”
Usually false. The holding is as of quarter end, not filing day.
Misconception 2: “A huge value means a fresh aggressive bet.”
Not always. For index-heavy managers, large values can reflect
long-standing benchmark exposure.
Misconception 3: “One quarter is enough to call a trend.”
You need at least two quarters to distinguish one-off noise from
consistent positioning.
FAQ
Short answers are below, and full FAQ structured data is included with this article.
- How long is the usual lag? Up to 45 days after quarter end.
- Is 13F useless because of lag? No. It is still very useful for medium-term portfolio behavior.
- What is the best companion metric? Quarter-over-quarter position change plus portfolio weight context.
Related Research
Explore all researchQ1 2026 13F filings are due May 15, 2026. Track Berkshire, Millennium, Bridgewater and more. See expected filing dates, AI/sector themes, and how to access data the moment it drops.
Mar 31, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
IMC-Chicago filed a $275.42B Q4 2025 13F showing 84 new positions, 84 exits, and a book dominated by ETF, index, and derivative-style exposures.
Mar 29, 2026
Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.
Mar 30, 2026
Janus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.
Mar 30, 2026